Overview
KRYS market data
Price History
KRYS price chart
Valuation & Profitability
- P/E (TTM)
- 40.29 Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- $6.84 Diluted earnings per share over the trailing twelve months.
- Beta
- 0.47 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- 54.8% Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $136.73 – $382.54 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $9.7B · P/B 5.86 · P/S 22.09.
Company News
RBC Capital Initiates Coverage On Krystal Biotech with Outperform Rating, Announces Price Target of $400Benzinga · Aug 14, 2026, 2:15 PM
Citigroup Maintains Buy on Krystal Biotech, Raises Price Target to $386Benzinga · Aug 4, 2026, 3:28 PM
Krystal Biotech shares are trading lower after the company announced mixed Q2 financial results.Benzinga · Aug 3, 2026, 11:58 AM
8-K filing — Krystal Biotech, Inc. (KRYS)SEC EDGAR · Aug 3, 2026, 11:04 AM
Krystal Biotech Q2 EPS $1.79 Beats $1.66 Estimate, Sales $119.222M Miss $121.061M EstimateBenzinga · Aug 3, 2026, 11:00 AM
Krystal Biotech to Report Second Quarter 2026 Financial Results on August 3, 2026Globenewswire Inc · Jul 23, 2026, 9:15 PM
Why Tutor Perini Stock Trounced the Market on TuesdayThe Motley Fool · Jul 21, 2026, 11:15 PM
Krystal Biotech Files Response With USPTO on KB801 Patent Application; Discontinues Clinical Study To Advance KB801 Into Pivotal Trial; No Safety Concerns Observed; No Further Subject-level Updates From Discontinued Study; Pivotal Trial Results Expected In Due CourseBenzinga · Jul 21, 2026, 9:33 PM
Krystal Biotech To Replace Taylor Morrison Home In The S&P MidCap 400, And Tutor Perini To Replace Krystal Biotech In The S&P SmallCap 600 Effective Prior To The Opening Of Trading On Friday, July 24Benzinga · Jul 20, 2026, 9:18 PM
B of A Securities Maintains Buy on Krystal Biotech, Raises Price Target to $396Benzinga · Jul 14, 2026, 2:18 PM